Bio-Works Technologies AB (XSAT:BIOWKS) ROCE % : -47.59% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Works Technologies AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bio-Works Technologies AB's annualized ROCE % for the quarter that ended in Sep. 2024 was -47.59%.

Bio-Works Technologies AB ROCE % Historical Data

The historical data trend for Bio-Works Technologies AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Works Technologies AB ROCE % Chart

Bio-Works Technologies AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-58.58

-75.28

-12.81

-50.71

-97.97

Bio-Works Technologies AB Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-	-137.62	-103.50	-	-47.59

Bio-Works Technologies AB ROCE % Calculation

Bio-Works Technologies AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-54.731	/	( ( (91.613 - 23.921)	+	(62.152 - 18.119) )	/ 2 )
	=	-54.731	/	( (67.692	+	44.033)	/ 2 )
	=	-54.731	/	55.8625
	=	-97.97 %

Bio-Works Technologies AB's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-19.704	/	( ( (35.342 - 10.17)	+	(66.922 - 9.285) )	/ 2 )
	=	-19.704	/	( ( 25.172	+	57.637 )	/ 2 )
	=	-19.704	/	41.4045
	=	-47.59 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Bio-Works Technologies AB (XSAT:BIOWKS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bio-Works Technologies AB ROCE % Related Terms

Thank you for viewing the detailed overview of Bio-Works Technologies AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Works Technologies AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Works Technologies AB (XSAT:BIOWKS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Virdings alle 18, Uppsala, SWE, 75450

Website

https://www.bio-works.com

Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.

Bio-Works Technologies AB Headlines

No Headlines